Peptides at a Turning Point: What the FDA Meeting Means for the Future with Jim LaValle
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Peptides at a Turning Point: What the FDA Meeting Means for the Future with Jim LaValle
-
ナレーター：
-
著者：
Peptides are everywhere—but so are questions about safety, quality, access, and regulation.
In this episode of The Synergee Podcast, Kelly and Lori welcome back Jim LaValle for an inside look at the recent FDA advisory committee discussions surrounding peptides and what they could mean for the future of peptide therapy.
Jim shares what has changed since 2023, why gray-market and research-grade peptides are such a concern, and why provider oversight, quality, and monitoring matter.
They also discuss promising uses for peptides in areas like mitochondrial health, recovery, gut health, chronic pain, muscle preservation, and healthy aging.
Plus, Jim shares his own approach to longevity—and why movement, nutrition, sleep, recovery, and lifestyle still come before peptides.
A must-listen for anyone curious about where peptide therapy is headed and how to approach it safely and responsibly.